Journal of Neuro-Oncology

, Volume 29, Issue 3, pp 269–272 | Cite as

Chemotherapy for meningiomas

  • Athanassios P. Kyritsis


The most efficacious treatment for meningiomas is surgery. For incompletely resected or recurrent tumors, radiotherapy can be given. However, when the meningioma is unresectable and/or all other previous treatments have failed, immunotherapy or chemotherapy may be considered for malignant tumors and immunotherapy and hormone therapy may be considered for benign ones. Various chemotherapy treatments that have shown some efficacy in individual cases include combinations of Adriamycin and Dacarbazine or Ifosfamide and Mesna. The most effective immunotherapy appears to be administration of interferon-alpha, which is relatively non-toxic and easily tolerated. However, more studies are needed to better define the roles of these agents in the management of a recurrent, unresectable, or malignant meningiomas.

Key words

meningiomas adriamycin dacarbazine ifosfamide/mesna mifepristone interferon-alpha 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    LeMay DR, Bucci MN, Farhat SM: Malignant Transformation of Recurrent Meningioma with Pulmonary Metastases. Surg Neuro1 31: 365–8,1989Google Scholar
  2. 2.
    Bernstein M, Villamil A, Davidson G et al.: Necrosis in a meningioma following systemic chemotherapy. J Neurosurg 81:284–287,1994Google Scholar
  3. 3.
    Stewart DJ, Dahrouge S, Wee M et al.: Intraarterial cisplatin plus intravanous doxorubicin for inoperable recurrent meningiomas. J Neuro-Onc 24:189–194,1995Google Scholar
  4. 4.
    Wober-Bingol C, Wober C, Marosi C, et al.: Interferon-alfa-2b for meningioma. Lancet (letter) 345: 331,1995Google Scholar
  5. 5.
    Grunberg SM, Weiss MH, Spitz IM, et al.: Treatment of unresectable meningiomas with the anti-progestational agent mifepristone. J Neurosurg 74: 861–866,1991aGoogle Scholar
  6. 6.
    Lamberts SWJ, Tanghe HLJ, Avezaat CJJ et al.: Mifepristone (RU486) treatment of meningiomas. J Neurol Neurosurg Psych 55:486–490,1992Google Scholar
  7. 7.
    Chabner BA: Anticancer Drugs. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Principles and Practice of Oncology. JB Lippincott Co, Philadelphia, 1993, pp 325–340Google Scholar
  8. 8.
    Rosenberg SA: Principles and applications of biologic therapy. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Principles and Practice of Oncology. JB Lippincott Co, Philadelphia, 1993, pp 293–324Google Scholar
  9. 9.
    Kepes JJ: Meningiomas-Biology, Pathology, and Differential Diagnosis. New York: Masson Publishing USA, 1982, pp 17–19Google Scholar
  10. 10.
    Kyritsis AP: Evaluation and treatment of CNS neoplasms. In: Lechtenberg, R and Schutta, HS (eds) Practice Guidelines for Neurologic Therapy. Marcel Dekker, New York, 1996 (In press).Google Scholar
  11. 11.
    Schoenberg BS, Christine BW, Wisnant JP: Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 25: 705–712,1975Google Scholar
  12. 12.
    Adams EF, Schrell UMH, Fahlbusch R et al.: Hormonal dependency of cerebral meningiomas: in vitro effect of steroids, bromocriptine, and epidermal growth factor on growth of meningiomas. J Neurosurg 73: 750–755,1990Google Scholar
  13. 13.
    Magdelenat H, Pertuiset BF, Poisson M, et al.: Progestin and oestrogen receptors in meningiomas. Biochemical characterization, clinical and pathological correlations in 42 cases. Acta Neurochir 64:199–213,1982Google Scholar
  14. 14.
    Schrell UMH, Adams EF, Fahlbusch R et al.: Hormonal dependency of cerebral meningiomas: female sex steroid receptor and their significance as specific markers for adjuvant medical therapy. J Neurosurg 73:743–749,1990Google Scholar
  15. 15.
    Grunberg SM, Daniels AM, Muensch H, et al.: Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem-cell assay. J Neurosurg 66: 405–408, 1987Google Scholar
  16. 16.
    Maiuri F, Montagnani S, Gallicchio B, et al.: Estrogen and progesterone sensitivity in cultured meningioma cells. Neurol Res 11: 9–13,1989Google Scholar
  17. 17.
    Waelti ER, Markwalder T-M: Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on growth of primary meningioma cells in monolayer tissue culture. Surg Neurol 31: 96–100,1989Google Scholar
  18. 18.
    Grunberg SM, Weiss M, Spitz I et al.: Treatment of meningioma with the oral antiprogestational agent mifepristone (RU486). Proc Annu Meet Am Soc Clin Oncol 10: A371, 1991bGoogle Scholar
  19. 19.
    Koper JW, Zwarthoff EC, Hagemeijer A et al.: Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer 27: 416–419,1991Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Athanassios P. Kyritsis
    • 1
  1. 1.Department of Neuro-OncologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Department of Neuro-Oncologyepartment of Neuro-Oncologyepartment of Neuro-OncologyThe U.TM.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations